

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
SHETTY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/011652

FILED: 15 OCTOBER 2004

U.S. APPLICATION NO: 10/574,745

35 USC §371 DATE:

FOR: COMBINATIONS OF AN ALDOSTERONE RECEPTOR
ANTAGONIST, A DIURETIC AND AN ANGIOTENSION BLOCKER

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R.
§1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to
the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these
references are of record in the instant PCT application PCT/EP2004/011652, copies are not
enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Pharma Intellectual Property
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9499



Joseph T. Majka
Attorney for Applicants
Reg. No. 30,570

Date: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
SHETTY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/011652

FILED: 15 OCTOBER 2004

U.S. APPLICATION NO: 10/574,745

35 USC §371 DATE:

FOR: COMBINATIONS OF AN ALDOSTERONE RECEPTOR
ANTAGONIST, A DIURETIC AND AN ANGIOTENSION BLOCKER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Pharma Intellectual Property
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9499
Date: *June 17, 2009*



Joseph T. Majka
Attorney for Applicants
Reg. No. 30,570